Ascendis Pharma A/S (ASND)
NMS – Real vaqt narxi. Valyuta: USD
237.65
-1.02 (-0.43%)
Yopilishda: May 12, 2026, 4:00 PM EDT
Find any stock by ticker or company name

NMS – Real vaqt narxi. Valyuta: USD
237.65
-1.02 (-0.43%)
Yopilishda: May 12, 2026, 4:00 PM EDT
Ascendis Pharma A/S Yevropa, Qo'shma Shtatlar va xalqaro miqyosda tibbiy ehtiyojlarni qondirish uchun TransCon asosidagi terapiyalarni ishlab chiqishga qaratilgan biofarmatsevtika kompaniyasi sifatida faoliyat yuritadi. Kompaniya o'sish gormoni etishmovchiligi bo'lgan bolalarni davolash uchun SKYTROFA; va surunkali gipoparatiroidizm bilan og'rigan kattalarni davolash uchun kuniga bir marta ter underiga yuboriladigan YORVIPATHni taklif etadi. Shuningdek, u klinik rivojlanish bosqichidagi uchta mustaqil endokrinologiya noyob kasalliklari mahsulot nomzodlarining portfelini ishlab chiqmoqda, shuningdek, onkologiya terapevtik nomzodlarini ilgari surishga qaratilgan. Kompaniya 2006 yilda tashkil etilgan va Daniyaning Hellerup shahrida joylashgan.
| Ism | Lavozim |
|---|---|
| Dr. Kennett Sprogoe Ph.D. | Executive VP and Head of Research & Product Development |
| Dr. Stina Singel M.D., Ph.D. | Executive VP & Head of Clinical Development for Oncology |
| Mr. Chad Fugure | Vice President of Investor Relations |
| Mr. Flemming Steen Jensen | Executive Vice President of Product Supply & Quality |
| Mr. Joseph Kelly | Head of U.S. Commercial of Endocrinology |
| Mr. Mads Bodenhoff | Senior VP, Head of Finance & Principal Accounting Officer |
| Mr. Michael Wolff Jensen L.L.M. | Executive VP, Chief Legal Officer & Member of the Executive Board |
| Sana | Turi | Hujjat |
|---|---|---|
| 2026-05-07 | 6-K | d121855d6k.htm |
| 2026-04-21 | 6-K | d139196d6k.htm |
| 2026-04-20 | 8-A12B/A | d51268d8a12ba.htm |
| 2026-04-20 | 6-K | d620541d6k.htm |
| 2026-04-16 | 6-K | d134243d6k.htm |
| 2026-04-08 | 6-K | d118310d6k.htm |
| 2026-04-07 | 6-K | d121667d6k.htm |
| 2026-03-30 | 6-K | d127945d6k.htm |
| 2026-03-24 | 6-K | d192884d6k.htm |
| 2026-03-17 | 6-K | d95087d6k.htm |